within Pharmacolibrary.Drugs.ATC.L;

model L01EC02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0703,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0125,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.294,
    k12             = 22,
    k21             = 22
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dabrafenib is an oral targeted anti-cancer drug classified as a BRAF inhibitor. It is used primarily for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation. It is also approved for use in combination with other agents for certain other cancer indications. It is widely used and approved for these purposes in clinical practice as of 2024.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with metastatic melanoma. Data derived from phase I/II trial patients, mixed sex, normal kidney and liver function.</p><h4>References</h4><ol><li><p>Puszkiel, A, et al., &amp; Blanchet, B (2019). Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib. <i>Clinical pharmacokinetics</i> 58(4) 451–467. DOI:<a href=&quot;https://doi.org/10.1007/s40262-018-0703-0&quot;>10.1007/s40262-018-0703-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30094711/&quot;>https://pubmed.ncbi.nlm.nih.gov/30094711</a></p></li><li><p>Flaherty, KT, et al., &amp; Weber, J (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>The New England journal of medicine</i> 367(18) 1694–1703. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1210093&quot;>10.1056/NEJMoa1210093</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23020132/&quot;>https://pubmed.ncbi.nlm.nih.gov/23020132</a></p></li><li><p>Denton, CL, et al., &amp; Ouellet, D (2013). Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors. <i>Journal of clinical pharmacology</i> 53(9) 955–961. DOI:<a href=&quot;https://doi.org/10.1002/jcph.127&quot;>10.1002/jcph.127</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23846776/&quot;>https://pubmed.ncbi.nlm.nih.gov/23846776</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EC02;
